Tag: ms

Pressemeldinger

BIOGEN IDEC COMPLETES PURCHASE OF FULL RIGHTS AND CONTROL OF TYSABRI®

BIOGEN IDEC COMPLETES PURCHASE OF FULL RIGHTS AND CONTROL OF TYSABRI®

03-04-2013 11:30

BIOGEN IDEC’S TECFIDERA™ (DIMETHYL FUMARATE) APPROVED IN US AS A FIRST-LINE ORAL TREATMENT FOR MULTIPLE SCLEROSIS

BIOGEN IDEC’S TECFIDERA™ (DIMETHYL FUMARATE) APPROVED IN US AS A FIRST-LINE ORAL TREATMENT FOR MULTIPLE SCLEROSIS

03-04-2013 11:24 Offers a Broad Spectrum of Patients with Relapsing Forms of MS an Effective and Convenient Treatment Option - - Reduces Relapses and Disability Progression - - Strengthens Biogen Idec’s Portfolio of Innovative Treatments for People Living with MS -

TYSABRI® (natalizumab) DATA AT ECTRIMS REAFFIRM POSITIVE EFFECTS OF TREATMENT FOR PEOPLE WITH RELAPSING FORMS OF MS

TYSABRI® (natalizumab) DATA AT ECTRIMS REAFFIRM POSITIVE EFFECTS OF TREATMENT FOR PEOPLE WITH RELAPSING FORMS OF MS

17-10-2012 13:25

Se alle 10 pressemeldinger »

Bilder

Oppskaket dame

Oppskaket dame

06-05-2011 14:36

Mann på benk

Mann på benk

06-05-2011 14:33

Dokumenter

Biogen Idec Pipeline

Biogen Idec Pipeline

06-05-2011 14:31

BIIB image

BIIB image

06-05-2011 14:31

Kontaktpersoner

Glenn Gundersen

Glenn Gundersen - Medisinsk sjef

Medisinsk ansvarlig for Biogen Idec's legemiddel portefølje, klinisk forskning og regulatoriske oppgaver